COMMUNIQUÉS West-GlobeNewswire

Agomab Announces Results of Annual General Meeting
27/05/2026
Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM [...]
BrewDog Turns This Summer’s Global Football Tournament into a Nationwide Celebration of Beer, Bars and Big Match Moments
27/05/2026
BrewDog Launches Multi-Channel “Underdog” Campaign Across Retail, Bars and Digital Media — Including a Nationwide “Win a Year of Beer” Contest and Destination Match-Day Watch Parties Across the U.K. ELLON, United [...]
Satellos to Participate in Upcoming Investor Conferences
27/05/2026
TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat [...]
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
27/05/2026
Investigational Oral Candidate JOTROL ™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: [...]
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
27/05/2026
Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, [...]
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
27/05/2026
Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt Combined with company's current total cash of $1.3 [...]
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
27/05/2026
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical- [...]
MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions
27/05/2026
Poster to be presented at ADA 2026 on weight loss induced by MTRX31 in an industry-standard preclinical model of obesity MitoRx Chief Scientific Officer Xavier Jacq to also participate in panel and deliver corporate [...]
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
27/05/2026
PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the [...]
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
27/05/2026
Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejection Phase 2 investigator-initiated study in [...]
HNL Lab Medicine Receives Accreditation from the College of American Pathologists
27/05/2026
ALLENTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) following a recent on-site inspection [...]
Korro to Present at the 2026 Jefferies Global Healthcare Conference
27/05/2026
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform to develop a new [...]
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
27/05/2026
Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP) DSAP is a serious, rare, premalignant [...]
InnoCare Announces Approval of Orelabrutinib in Australia
27/05/2026
BEIJING, May 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that orelabrutinib (HIBRUKA ® ) has [...]
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
27/05/2026
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
27/05/2026
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, [...]
Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol “SKYA”; Establishing Category-defining Agentic Finance Platform Serving Global South
27/05/2026
Rebrand to SkyAI, Inc. to reflect evolution of the business to build a global agentic finance platform Opened operational headquarters in Hong Kong, a global hub for financial technology innovation and a base for [...]
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
27/05/2026
Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E Virus BOSTON, May 27, 2026 [...]
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
27/05/2026
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio [...]

Pages